Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 8/20 | 0.64 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.52 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.51 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7043078 | 0.87 | JAK1 (0.60) | PDE4DPDE10AJAK1KDM4EHSP90AB1 | |
| SCHEMBL7144538 | 0.87 | PDE4D (0.49) | PDE4DPDE10AJAK1KDM4EHSP90AB1 | |
| SCHEMBL2257907 | 0.86 | MAPT (0.49) | PDE4DPDE10AJAK1KDM4EHSP90AB1 | |
| SCHEMBL7146898 | 0.86 | KDM4E (0.51) | PDE4DPDE10AJAK1KDM4E | |
| SCHEMBL7043841 | 0.85 | MAPT (0.51) | PDE4DPDE10AJAK1KDM4EHSP90AB1 | |
| SCHEMBL7145674 | 0.85 | PDE10A (0.50) | PDE4DPDE10AJAK1HSP90AB1 | |
| SCHEMBL6876513 | 0.84 | PDE4D (0.48) | PDE4DPDE10AJAK1MAPT | |
| SCHEMBL7146570 | 0.84 | PDE4D (0.48) | PDE4DPDE10ANUDT1JAK1MAPT | |
| SCHEMBL7143153 | 0.83 | PDE4D (0.46) | PDE4DPDE10AJAK1KDM4EHSP90AB1 | |
| SCHEMBL7143142 | 0.82 | JAK2 (0.48) | PDE4DPDE10ANUDT1HSP90AB1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1412352-A1 | 8-METHOXY-(1,2,4)TRIAZOLO(1,5-A)PYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-28 | — | — | EP | claimed |
| WO-2003010167-A1 | 8-METHOXY-(1,2,4)TRIAZOLO(1,5-A)PYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-02-06 | — | — | WO | claimed |
| US-6514989-B1 | Has a good affinity to the adenosine receptor and can therefore be used for the treatment or protection of diseases mediated by this receptor | HOFFMANN-LA ROCHE INC. | 2003-02-04 | — | — | US | claimed |
| EP-2531503-A1 | GAMMA SECRETASE MODULATERS | F. Hoffmann-La Roche AG (CH) | 2012-12-12 | — | — | EP | disclosed |
| WO-2011092272-A1 | GAMMA SECRETASE MODULATERS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-04 | — | — | WO | disclosed |
| US-20110190269-A1 | GAMMA SECRETASE MODULATORS | HOFFMANN-LA ROCHE, INC. | 2011-08-04 | — | — | US | disclosed |
| EP-1412352-A1 | 8-METHOXY-(1,2,4)TRIAZOLO(1,5-A)PYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003010167-A1 | 8-METHOXY-(1,2,4)TRIAZOLO(1,5-A)PYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-02-06 | — | — | WO | disclosed |
| US-6514989-B1 | Has a good affinity to the adenosine receptor and can therefore be used for the treatment or protection of diseases mediated by this receptor | HOFFMANN-LA ROCHE INC. | 2003-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190269-A1 | GAMMA SECRETASE MODULATORS | BACE1, APH1A, APH1B | PDE4D 1171/4885PDE10A 934/4885NUDT1 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.